These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27296805)

  • 1. [The congress of the French Society of Pharmacology and Therapeutics celebrate in Nancy, 20 April 2016, 40 years of French Regional Pharmacovigilance Centres!].
    Jonville-Béra AP; Mallaret M; Sgro C;
    Therapie; 2016 Sep; 71(4):351-4. PubMed ID: 27296805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [From psychoactive medicines to addictovigilance in French Public Health Code (1990-2017)].
    Baumevieille M; Perri-Plandé J; Miremont-Salamé G; Daveluy A; Haramburu F
    Therapie; 2019 Jun; 74(3):375-382. PubMed ID: 30193805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: a win-win bet with Health Authorities!].
    Jonville-Bera AP; Gautier S; Micallef J; Massy N; Atzenhoffer M; Drici MD; Grandvuillemin A;
    Therapie; 2023; 78(5):477-488. PubMed ID: 36890032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
    Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
    Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Update of the French drug reaction assessment method].
    ; Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB
    Therapie; 2011; 66(6):517-25. PubMed ID: 22186077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The French pharmacovigilance system: structure and missions].
    Welsch M; Alt M; Richard MH; Imbs JL
    Presse Med; 2000 Jan; 29(2):102-6. PubMed ID: 10682040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collaboration Between Health-Care Professionals, Patients, and National Competent Authorities Is Crucial for Prevention of Health Risks Linked to the Inappropriate Use of Drugs: A Position Paper of the ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé).
    Vignot S; Daynes P; Bacon T; Vial T; Montagne O; Albin N; Emmerich J; Ratignier-Carbonneil C; Martin D; Maison P
    Front Pharmacol; 2021; 12():635841. PubMed ID: 33995037
    [No Abstract]   [Full Text] [Related]  

  • 10. [Not Available].
    ; Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB
    Therapie; 2011; 66(6):517-25. PubMed ID: 27393472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Court of Justice. ECJ 2014/6 Octapharma France SAS v. Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), Ministère des Affaires Sociales et de la Santé, 13 March 2014 (C-512/12).
    Baeyens A; Goffin T
    Eur J Health Law; 2014 Jun; 21(3):317-21. PubMed ID: 25065041
    [No Abstract]   [Full Text] [Related]  

  • 12. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acute cough in infants: impact on families and pharmacists of contraindications of the Agence nationale de sécurité du médicament et des produits de santé (ANSM)].
    Alauzet F; Blanc S; Montaudié I; Piccini-Bailly C; Berlioz-Baudoin M; Bégassat M; Albertini M; Giovannini-Chami L
    Arch Pediatr; 2014 May; 21(5):469-75. PubMed ID: 24726669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacovigilance and drug-induced rare diseases: Strengths of the French Network of Regional Pharmacovigilance Centres.
    Lacroix C; Mallaret M; Jonville-Bera AP
    Therapie; 2020 Apr; 75(2):207-213. PubMed ID: 32113688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early access to health products in France: Major advances of the French "Conseil stratégique des industries de santé" (CSIS) to be implemented (modalities, regulations, funding).
    Albin N; Chassagnol F; Bergmann JF; ;
    Therapie; 2019 Feb; 74(1):103-117. PubMed ID: 30745156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Organisation of clinical research in France: the new missions of inter-regional delegations for clinical research].
    Jaillon P
    Bull Acad Natl Med; 2008 May; 192(5):929-37; discussion 937-9. PubMed ID: 19238783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reactions in patients older than 70 years during the heat wave occurred in France in summer 2003: A study from the French PharmacoVigilance Database.
    Michenot F; Sommet A; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
    Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):735-40. PubMed ID: 16924603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is the collecting activity of regional pharmacovigilance centers influenced by regional demographic or health determinants?].
    Lam L; Desitter C; Maison P
    Therapie; 2019 Jun; 74(3):333-341. PubMed ID: 30173895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of reports on early access programs for checkpoint inhibitors in cancer patients: a French retrospective nationwide cohort study.
    Chatain A; Fenioux C; Lamé G; Bouras A; Babai S; Ahmed ES; Monard A; Manuceau G; Tournigand C; Albin N; Kempf E
    ESMO Open; 2024 Nov; 9(11):103711. PubMed ID: 39395267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.